ILCA 2023 | Liquid Biopsy Technology Based on Methylated SEPT9 Has the Potential to Establish a New Early Diagnosis System for Liver Cancer

ILCA 2023 | Liquid Biopsy Technology Based on Methylated SEPT9 Has the Potential to Establish a New Early Diagnosis System for Liver Cancer

 Liver cancer is one of the malignant tumors with a high incidence and mortality rate in China. Most patients are clinically diagnosed late, with a high rate of postoperative recurrence and metastasis, which has become a significant factor affecting patient prognosis. There is an urgent need for technology that can effectively detect early liver cancer, monitor treatment effects in real-time, and prevent metastasis. Liquid biopsy technology has attracted attention in recent years as a new detection method. It is non-invasive, sensitive, and dynamic, showing promise in early tumor diagnosis, personalized medication guidance, and treatment monitoring. At the 17th International Liver Cancer Association Annual Meeting (ILCA 2023), Dr. Issei Saeki from School of Medicine of Yamaguchi University,Japan, reported a study (Abstract number: O-11) that assessed the clinical application value of liquid biopsy technology based on the methylated SEPT9 test for early diagnosis of non-viral hepatitis-related hepatocellular carcinoma (N-HCC).
ILCA 2023 | When HIV Infection Coexists with HCC: Patient Clinical Features, Treatment Status, and Outcomes

ILCA 2023 | When HIV Infection Coexists with HCC: Patient Clinical Features, Treatment Status, and Outcomes

 After the HIV virus enters the human body, it first destroys the immune system, leading to a rapid decline in immunity. Consequently, the body becomes more susceptible to various infections and complications, the most common of which are infections in different systems and malignant tumors. As the life expectancy of people living with HIV (PLWH) increases, cases of coexisting malignant tumors are also on the rise. From September 7-9, 2023, the seventeenth International Liver Cancer Association (ILCA) annual meeting (ILCA 2023) was grandly held in Amsterdam, the capital of the Netherlands. At this conference, Dr. Eleonora Alimenti from the University of Pavia, Italy, orally presented the clinical features, treatment status, and clinical outcomes of PLWH coexisting with HCC at Lombardy's Third Hospital in Italy (Conference Abstract: O-07), drawing significant attention.
Dr. Qiang Gao: The Complexity and Diversity of Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma

Dr. Qiang Gao: The Complexity and Diversity of Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma

 Intrahepatic cholangiocarcinoma (ICC) refers to adenocarcinoma originating from the epithelium of secondary bile ducts and their branches, accounting for 10%-15% of primary malignant tumors in the liver. In recent years, the incidence of ICC has been rising significantly, garnering increasing clinical attention. While ICC and hepatocellular carcinoma (HCC) both belong to primary liver cancers, they have distinct biological characteristics. The complex disease characteristics and prognosis pose significant challenges for ICC's clinical treatment. From September 7-9, 2023, the 17th annual meeting of the International Liver Cancer Association (ILCA) was grandly held in Amsterdam, Netherlands. At the conference, Dr. Qiang Gao from Zhongshan Hospital, Fudan University, China, shared recent advancements in the study of tumor-immune interactions in ICC. This article compiles an in-depth interview with Dr. Gao for our readers.
Insights from ASCO GU: An Exclusive Interview with UBC’s Marie-Pier St-Laurent | Oncology Frontier

Insights from ASCO GU: An Exclusive Interview with UBC’s Marie-Pier St-Laurent | Oncology Frontier

Welcome to a special feature by Oncology Frontier, where we bridge the gap between continents in the realm of medical innovation. Today, we're honored to host Marie-Pier St-Laurent from the University of British Columbia. As part of our exclusive Specialist Interview series, Marie-Pier will be sharing valuable insights from her recent abstract presented at ASCO GU. Stay tuned as we delve into groundbreaking research that's shaping the future of oncological care. Visit us at www.ioncol.com for more thought-provoking content
Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

The 28th European Hematology Association (EHA) Congress was held from June 8th to June 11th, 2023, in Frankfurt, Germany, in a hybrid format combining online and offline meetings. As the largest international conference in the field of European hematology, the EHA Congress covered a wide range of scientific topics, clinical and basic research, including both benign and malignant hematology, discussing the latest developments in the field. Regarding the treatment of Myelofibrosis (MF), several studies from Dr. Jie Jin's team at the First Affiliated Hospital of Zhejiang University (abstracts S212, P1201, and P1033) were selected for this congress. These studies focused on exploring the efficacy and safety of the new JAK inhibitor Jaktinib in the treatment of MF, attracting significant attention due to its clinical significance. In this regard, Oncology Frontier conducted an on-site interview with Professor Jin Jie and provided a brief explanation of this topic.
Dr. Wei Jia’s Team Achieves Fruitful Results on EHA 2023

Dr. Wei Jia’s Team Achieves Fruitful Results on EHA 2023

From June 8th to 11th, the 28th European Hematology Association (EHA) Annual Congress was held in a combined online and offline format in Frankfurt, Germany. Top global experts in hematology shared various scientific themes, clinical and basic research, discussing cutting-edge achievements. Dr. Wei Jia’s team, currently stationed at Tongji Shanxi Hospital, Director of the Hematology Department at Shanxi Baiqiu'en Hospital, China, had three research results selected for presentation. Oncology Frontier specially invited Dr. Wei to present the findings.
Dr. Komrokji Shares Latest International Classification and Treatment Advancements in Myelodysplastic Syndromes

Dr. Komrokji Shares Latest International Classification and Treatment Advancements in Myelodysplastic Syndromes

Dr. Komrokji delved into the revised classifications for Myelodysplastic Syndromes (MDS) unveiled at the International Congress. The discussion contrasted the 2016 and 2022 editions, spotlighting new molecularly defined subcategories, such as SF3B1 MDS and biallelic p53, alongside morphological distinctions like MDS with increased blast types, hypoplastic MDS, and MDS with fibrosis. Dr. Komrokji's insights underscored the evolving MDS classification landscape and promising therapeutic frontiers, marking a pivotal advancement in understanding MDS and refining patient care.
Dr. Nigel Russell: The Latest International Treatment Advances in Acute Myeloid Leukemia

Dr. Nigel Russell: The Latest International Treatment Advances in Acute Myeloid Leukemia

Abstract: Dr. Nigel Russell provides insights into the recent developments in the treatment landscape of Acute Myeloid Leukemia (AML). The discussion encompasses the combination of FLT3 mutation inhibitors with intensive chemotherapy, emphasizing the effectiveness and safety demonstrated by the combination of midostaurin with gemtuzumab ozogamicin. The presentation explores emerging FLT3 inhibitors like quizartinib and their potential in combination with chemotherapy. Additionally, Dr. Russell delves into a groundbreaking study involving the combination of the FLAG-Ida regimen with gemtuzumab ozogamicin for patients with NPM1-mutated AML. The study reveals significantly improved event-free and overall survival, indicating a promising therapeutic approach for this patient subgroup. Furthermore, the discussion touches upon the advancements in bispecific antibodies in AML, particularly focusing on blinatumomab's role in targeting CD19 for patients with relapsed core-binding factor leukemia. The potential use of bispecific antibodies in eradicating minimal residual disease after intensive therapy is highlighted, offering a glimpse into a targeted therapeutic strategy for AML patients. Overall, these insights contribute to the evolving landscape of AML treatment, showcasing promising avenues for improving patient outcomes.